Management Team

Neil H. Parikh, Ph.D.
Neil H. Parikh is responsible for overall operation and management of the company. He holds a Ph.D. in Industrial Pharmacy. He has extensive experience in US Pharmaceutical Industry both in brand and generic drug sectors. Most recently he was the Vice President of Generic Research and Development at Watson Laboratories, California, USA. He had over 150 product registrations and over 100 product approvals with several first to file opportunities. He is well-versed in identification, development, registration and commercialization of solid oral (immediate release and extended release), transdermals/gels, medicated chewing gums and respiratory drug products.

Anandi Krishnan, Ph.D.
Anandi Krishnan is responsible for Scientific/Regulatory matters of the company. She has 16 years of varied experience in the research and development of pharmaceutical dosage forms. She has worked with leading Indian organizations such as Cipla, Sun Pharma, and most recently Glenmark Pharmaceuticals, and was the key person responsible for Glenmark's U.S. ANDA (Abbreviated New Drug Application) filings. She has 20 patent filings to her credit and has worked on products for the U.S., European and Australian markets.

MATTHEW PINO
Matthew Pino is the Head of Business Development and Operations - Americas at Getz Pharma Research (GPR). In this position he is responsible for leading Sales & Marketing and Business Operations for the strategic and commercial efforts of the pharmaceutical contract product development and manufacturing services business.

Mr. Pino received his B.S. degree in Biotechnology at Rochester Institute of Technology. Having joined GPR with over 16 years of experience in manufacturing operations and business development in the pharmaceutical and biotechnology industry spending much of his career with Regeneron, Idec, Cardinal and Catalent. His broad background in drug product development and commercialization ranges from a variety of roles held in manufacturing operations and strategic account management portfolios in excess of $50m.